Brii Biosciences Competitors and Similar CompaniesClear all
Brii Biosciences's competitors and similar companies include Benchmark Research, WuXi AppTec, Molecular Partners and Y-mAbs Therapeutics.
 Brii Biosciences Brii Biosciences researches and develops medicines for the treatment of chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. |  Benchmark Research Benchmark Research is a clinical research firm that conducts investigational studies for the development of vaccines and medicines. |  WuXi AppTec WuXi AppTec (无锡药明康德新药开发股份有限公司, formerly known as WuXi PharmaTech) is a company that provides integrated research, development, and manufacturing solutions for drug discovery and production. |  Molecular Partners Molecular Partners is a company that develops biopharmaceutical products for serious diseases. |  Y-mAbs Therapeutics Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. | |
Founding Date | Founding Date 2018 | Founding Date 1997 | Founding Date 2000 | Founding Date 2004 | Founding Date 2014 |
Type | Type Private | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations CN HQ Beijing, CN Durham, US San Francisco, US San Mateo, US | Locations Austin, US HQ Colton, US Fort Worth, US Metairie, US Sacramento, US San Angelo, US San Francisco, US see more | Locations Shanghai, CN HQ Beijing, CN Changzhou, CN Chengdu, CN Nanjing, CN Nantong, CN Shanghai, CN see more | Locations Zürich-Schlieren, CH HQ Cambridge, US Concord, US | Locations New York, US HQ Copenhagen, DK Nutley, US |
Employees | Employees 8510% decrease | Employees 719% decrease | Employees 39,414 | Employees 158 | Employees 3239% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 20.7 b | Valuation ($) N/A | Valuation ($) 657 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ¥43.1b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $87.7m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥23.8b (FY, 2025) | Cost of goods N/A | Cost of goods $15m (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit ¥21.3b (FY, 2025) | Gross profit N/A | Gross profit $72.7m (FY, 2024) |
Net income | Net income N/A | Net income N/A | Net income ¥19.3b (FY, 2025) | Net income (CHF61.7m) (FY, 2025) | Net income ($29.7m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 415m | Total funding raised N/A | Total funding raised $ 902.6m | Total funding raised N/A | Total funding raised $ 80m |
For sources of this data, please see the company profile
View Company Profiles
Benchmark Research
HQ
Austin, US
Employees
71↓ 9% decrease
Benchmark Research is a clinical research firm that conducts investigational studies for the development of vaccines and medicines.
View companyWuXi AppTec
HQ
Shanghai, CN
Employees
39,414
WuXi AppTec (无锡药明康德新药开发股份有限公司, formerly known as WuXi PharmaTech) is a company that provides integrated research, development, and manufacturing solutions for drug discovery and production.
View companyMolecular Partners
HQ
Zürich-Schlieren, CH
Employees
158
Molecular Partners is a company that develops biopharmaceutical products for serious diseases.
View companyY-mAbs Therapeutics
HQ
New York, US
Employees
32↑ 39% increase
Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets.
View company